Silence Therapeutics plc (NasdaqGM: SLN) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Silence Therapeutics plc (NasdaqGM: SLN) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of Silence will receive $20.00 in cash for each share of Silence that they own. The firm is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.